- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$31.57 BnMarket Estimate, 2026
$32.39 BnMarket Forecast, 2034
$39.77 BnCAGR, 2026–2034
2.6%Middle East and Africa Next Generation Antibody Therapeutics Market Size
The Middle East and Africa next-generation antibody therapeutics market was valued at USD 31.57 billion in 2025, is estimated to reach USD 32.39 billion in 2026, and is projected to reach USD 39.77 billion by 2034, growing at a CAGR of 2.60% from 2026 to 2034.
MARKET DRIVERS
Advancements in Monoclonal Antibody Technologies
Next generation antibody therapeutics have high efficiency and are safer. Rapid advancements in monoclonal antibodies technology are the reason for this. These advances have improved bifunctional properties, decreased functional size along with immunogenicity. Several medical conditions like cancer; autoimmune diseases, etc. are treated using these technologies because of its enhanced properties.
A rising number of cases of chronic diseases, rapid advancements in technology, higher investment in R&D and increasing healthcare expenditure are the primary drivers of market growth.
MARKET RESTRAINTS
On the other hand, strict administrative guidelines and regulatory requirements and inordinate delays in approval for new drugs along with their high costs are the primary restraints of market growth.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Therapeutics, Technology, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of Middle East and Africa |
| Market Leaders Profiled | Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc. |
KEY MARKET PLAYERS
Key Market Companies dominating the Middle East & Africa Next Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.
MARKET SEGMENTATION
The Middle East & Africa Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories
By Therapeutics
- Oncology
- Autoimmune/Inflammatory Diseases
By Technology
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies (BsAbs)
- Fc Engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
By Country
- KSA
- UAE
- Israel
- Rest of GCC Countries
- South Africa
- Ethiopia
- Kenya
- Egypt
- Sudan
- Rest of MEA